• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom Q4 earnings miss by a penny — but revenue up 23%

February 12, 2021 By Chris Newmarker

Dexcom updated logoDexcom (NSDQ:DXCM) reported mixed Q4 2020 results and reiterated a fiscal year 2021 revenue guidance that is slightly below Wall Street projections.

The San Diego–based continuous glucose monitor company yesterday evening reported profits of $355.2 million, or $3.48 per share, on sales of $568.9 million for the three months ended Dec. 31, 2020, nearly quadrupling the bottom line on 23% sales growth compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were 91¢, a penny behind The Street, where analysts were looking for EPS of 92¢ on sales of $552.88 million.

Dexcom CEO Kevin Sayer in a news release described 2020 as “another strong year for Dexcom, culminating with record annual new patient additions and absolute dollar revenue growth, and our highest gross margin quarter in the past five years.”

“We are making excellent progress on our strategic objectives as we press forward to bring Dexcom CGM to the many people around the world who stand to benefit from better glycemic control,” Sayer said.

Sayer added during the following earnings call that the work on the company’s next-gen G7 CGM remains on track: “Our clinical work is continuing as we progress with the regulatory path in 2021 to support our goal to launch G7 in the second half of the year.” He later clarified that some markets may have to wait until early 2022.

The company is reiterating guidance for fiscal year 2021 revenue of roughly $2.21–2.31 billion, representing 15–20% growth but also slightly behind the Wall Street consensus of $2.33 billion. Dexcom is also projecting a non-GAAP gross profit margin of approximately 65% this year.

“We’re very bullish on some of these new market opportunities and contributions that can come from them, but we’re not going to get ahead of ourselves with respect to those expectations as they play out,” Dexcom CFO Quentin Blackford said during the earnings call.

Dexcom has announced a number of initiatives to fuel growth, including a plan to double its sales force and scale-up direct-to-consumer marketing. The company is also ramping up manufacturing in Malaysia, where it has its first manufacturing site outside of the U.S. There’s a new global business services unit in Lithuania. Plus, Dexcom has also established an inaugural venture capital fund.

UBS analysts after the call reiterated their buy rating for DCXM shares and raised their price target: “While DXCM is sacrificing some near term margin, we like the strategy to go on offense to attack this huge [total available market].”

Investors reacted by sending DCXM shares down –4.3% in after-hours trading yesterday. But by the next morning, shares were only down –1.52%, trading at $403.97 apiece. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up slightly this morning.

This story originally ran on Thursday, Feb. 11, after market close. Updated with additional details, including from earnings call. Pharma editor Brian Buntz contributed to this article. 

 

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: CGM, Dexcom, DexCom Inc., Diabetes

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS